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Tm object of rids study was to establish whether Sequential release of cytokines, different pro- and anti-inflammatonj mediators
were formed in colonic tissue from experimental lipid mediators and nitric oxide in
colitis depending on the course of the disease.
Concentrations of mediators of inflammation experilTlena[ 0o[itis
were examined in colonic tissue in dextran
induced colitis in mice. Initial inflammation was
produced by 5 days treatment of 10% dextran A.P.M. van Di]k,’c Z. J. Keuskamp,
sodium sulfate (DSS) in drinking water, followed J. H. P. Wilson
2 and F. J. Zijlstral by a further 9 day period of 2% DSS in an attempt
to produce a milder chronic inflammation. The
degree of inflammation was scored by a standard-
ized macroscopic and histological examination. 1Department of Pharmacology, Erasmus University,
Initially, a 60% maximum inflammation score was Rotterdam; and
observed at day 4. At this time inflammation was 2Department of Internal Medicine II, University
associated with the release of interleuldn-ll30L- Hospital Dijkzigt, Rotterdam, the Netherlands
113) and tumour necrosis factor-), whereas
both prostaglandins 6kPGFI and PGE2 and nitric
oxide (NO) markedly decreased. Then a 25% CACorresponding Author
inflammation score was reached which coincided
with an increased production of platelet-activat-
ing factor (PAF). No significant changes were
observed in leukotriene B and C formation. In
conclusion, pro-inflammatory cytokines IL-I and
TNF are considered to be primary mediators,
whereas PAF, eicosanoids and NO may reflect
secondary mediators in experimental colitis.
Key words: Dextran colitis in mice, Eicosanoids, IL-I,
NO, PAF, TNFz
Introduction bioregulator of eicosanoid and cytokine produc-
tion.
1 Since damage of the endothelial cell can
Several experimental models have been be a prime event leading to mucosal injury, this
described which resemble human inflammatory could reflect a diminished release of the endo-
bowel disease (IBD), including ulcerative colitis thelial derived mediators prostacyclin (PGI2) and
(UC) and Crohn’s disease (CD). These animal nitric oxide (NO). On the contrary, we have
models have been used to examine the produc- found high amounts of the 15-1ipoxygenase
tion of inflammatory mediators by intestinal product 15-hydroxy-eicosatetraenoic acid (15-
mucosa and to determine the effects of various HETE) in human colonic mucosa.
1 This sub-
drugs on inflammation and on individual media- stance is synthesized both by endothelial cells
tots.2’3 The customary drugs used in IBD--cort- and macrophages. The minor anti-inflammatory
icosteroids and 5-aminosalicylates--are thought effects of 15-H(P)ETE could be ascribed to
to act by interfering with eicosanoid produc- inhibition of the pro-inflammatory mediator
tion.
4 In IBD, the synthesis of leukotriene B4 LTB4.
2 It has been suggested that cytokines
(LTB4) in colonic mucosa has been shown to such as turnout necrosis factor (TNFa) and
be enhanced compared with its production in interleukin-I (IL-1) are primary triggers of the
normal tissue.5 However, specific 5-1ipoxygenase initial inflammation,
3 whereas platelet-activating
inhibitors such as Zileuton have not been factor (PAF)is considered to be involved as a
shown to have marked beneficial effects on secondary trigger, resulting in a chronic phase
inflammation in man, although LTB4 levels in of the inflammation.
4 This hypothesis implies
dialysates were decreased.
6 Prostaglandin E2 that the choice of drug therapy for IBD might
(PGE2) is also increased in dialysates
7 and depend on the stage of the disease. In the
mucosal tissues of patients with UC and CD. search for a suitable model for UC resembling
However, the anti-inflammatory effects of this acute, and chronic inflammation of colonic
substance are well documented,9 and it is there- mucosa, we modified the dextran sodium sulfate
fore likely that PGE2 mainly acts as a feed-back (DSS) induced colitis in mice and measured a
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wide range of mediators of inflammation during be done at the same time in one assay.
the course of the disease. Microscope evaluation of the colonic tissue
was assessed as follows: cell infiltration of the
Materials and Methods tissue; depletion of goblet cells; loss of the tissue
architecture; and the formation of crypt absces-
Induction of colitis: Colitis was induced in BALB/ ses (score 0-4). Each of the given parameters on
c female mice (20-22 g) by adding high-mole- macroscopic and microscopic evaluation was
cular dextran sodium sulfate (DSS; Pharmacia, subdivided into a three-scaled point system (+,
Sweden) to their drinking water, which was given + + and + + + ), resulting in a total inflamma-
to the mice ad libitum from the first day of the tion score range of 0-33 points, which served as
treatment. DSS, given orally, causes a diffuse an objective measure of the severity of inflamma-
inflammation of the mucosa of the entire gut. tion of the colonic tissue.
12
The mechanism by which this inflammation is
induced is not entirely clear, but bacterial flora in Measurement of mediators: The amount (mg) of
the gut appear necessary for the process.
15 protein per g wet homogenized tissue was deter-
During the treatment schedule, the concentration mined in the supematant by a micro-scale
of DSS in the water was altered. For the first 5 method (Instruchemie, Hilversum, The Nether-
days 10% (w/v) DSS was administered via the lands) using an ELISA reader (Biorad, USA) at
drinking water in an attempt to provide a model 600 nm. Myeloperoxidase (MPO) in these
for the acute and initial phase of inflammation, samples was determined by means of a double
During the last 9 days of the schedule, the con- antibody radioimmunoassay (RIA, Pharmacia,
centration was lowered to 2% (w/v) DSS, in Sweden) in which bound and free MPO were
order to create a more chronic and milder separated by addition of a second antibody
inflammation in the mucosa of the colon, immunosorbent and 125I was counted.
The concentrations of different mediators of
Treatment schedule: In this study 29 mice were inflammation were measured in duplicate in the
randomly divided into five groups. The first group liquid samples described above. The nitric oxide
consisted of nine mice and served as a control metabolites, nitrate (after reduction to nitrite) +
group throughout the investigation period. The nitrite, were measured colometrically after the
other 20 mice were divided into four groups of Griess reaction, as described by Phizackerly and
five mice each. The animals were killed by cervi- A1-Dabbagh.
16 Briefly, the following modifications
cal dislocation after 2, 4, 8 and 14 days. were applied:
7 samples were deproteinized by
adding 1M NaOH and 1.3 M ZnSO4; nitrate was
Experimental procedure and inflammation converted to nitrite by the addition of Klebsiella-
score: After the mice were killed, the colon from pneumonia suspension, 0.2 M N-tris-(hydroxy-
flexure to rectum was removed immediately. A methyl)-methyl-2-amino-ethane sulfonic acid
small piece was cut off and stored in form- (TES) and 0.5 M sodium formate; after anaerobic
aldehyde, and subsequently prepared for histo- incubation, water was added and nitrite was
logical examination. The colon was opened in assayed in supernatants. Nitrite was estimated in
a transverse direction and examined macro- deproteinized samples, mixed with 1% sulfanil-
scopically using a 10 x magnification. Signs of amide in 15% phosphoric acid; after the addition
inflammation and changes in the appearance of of 0.1% N-(1-naphthyl)ethylenediamine, the
the colonic mucosa were evaluated and the absorption was determined at 540 nm by means
severity of inflammation (erythema, haemor- of an ELISA reader (Biorad). The linear detection
rhages, mucus, oedema, strictures, diarrhoea) range was between 1 and 250 IM.
was scored (0-6). Faeces were also examined for Cytokines, eicosanoids and PAF were deter-
the presence of occult blood (score 0-1). After mined in the samples of the colonic tissue by
macroscopic assessment, the colon was incu- means of ELISAs and RIAs. For the assay of
bated in 5 ml 0.9% w/v saline and then shaken TNEc, a specific mouse TNFz ELISA kit was
lightly for 5 min. This suspension was centrifuged obtained from Genzyme Corp., using a hamster
(2800 x g, 10 min, 4C) and the supernatant monoclonal antibody specific for murine TNF, a
was stored at -80C. The colon was weighed goat polyclonal anti-murine TNF antibody, and,
and 2 ml KREBS buffer added. The colonic tissue as third antibody, horsedish peroxidase-con-
was fragmented in this solution using the Ultra- jugated donkey anti-goat Ig. The peroxidase
Turrax (Polytron, Switzerland), after which this enzyme reacted with peroxide substrate, after
suspension was centrifuged (10 000 x g, 10 min, which the colour intensity was measured at 492
4C) and the supernatant stored at -80C until nm. Detection range was between 0.05 and 1.6
measurements of inflammatory mediators could ng/ml. Measurements of IL-113 were performed
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FIG. 1. Macroscopic (O) and microscopic ((C)) inflammation
scores of mouse colonic mucosa (means + S.E.M.) after dextran
sodium sulfate application. *p < 0.05 vs. day O.
using a high sensitivity IL-lJ3 assay from Cistron
Biotechnology (Eurogenetics, Belgium), bound
to a solid phase monoclonal antibody, after
which in the second stage polyclonal rabbit anti-
IL-113 was added, followed by goat anti-rabbit IgG
conjugated to horseradish peroxidase enzyme
which reacts with peroxide substrate. The end
product was measured at 450 nm. Detection
range was between 4 and 250 pg/ml.
Eicosanoids were determined by RIA. Specific
antibodies were obtained from Advanced Mag-
netics Inc. (MA, USA), tritiated compounds from
Amersham (UK) and standards from Sigma Co.
(USA). Assays were performed for a 16 h compet-
itive binding period, using standard curves from
0-500 pg/tube; sensitivities were: PGE2, 2 pg/
tube; 6kPGFI=, LTB4 and LTC4, 5 pg/tube at 98%
B/Bo.
Finally, PAF was measured using a SPA-RIA kit
assay system of Amersham (UK). The standard
curve was prepared from 0 to 1280 pg/tube and
a sensitivity of 20 pg/tube. The concentrations of
the mediators produced during inflammation
were expressed per mg wet colonic tissue.
Statistics: Data are expressed as the mean ___
standard error of the mean (S.E.M.). Data were
analysed statistically with ANOVA followed by
Student’s t-test and p values < 0.05 (two-sided)
were considered significant.
Results
Inflammation score: The results of the macro-
scopic and microscopic inflammation scores are
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FIG. 2. Histological sections of rectal colonic mucosa; (a) section
from a control mouse in which no histological damage was
observed; (b) section of rectum after 4 days treatment With DSS
showing cell infiltration, goblet cell depletion and loss of archi-
tecture; (c) section of rectum after 8 days treatment with DSS
showing cell-less infiltration and some goblet cell depletion.
shown in Fig. 1. In the control group, which
contained mice that had not been treated with
DSS, no inflammatory activity was observed (Fig.
2(a)).
The group treated for 2 days with 10% DSS
solution and then killed at the second day of the
treatment schedule, showed a significant increase
in the inflammation score. The maximum inflam-
mation score was seen after 4 days treatment
with 10% DSS (Fig. 2(b)). The inflammation
score of the fourth and fifth group, in which theSequential mediator release in colitis
5000
2500-







FIG. 3. Production of prostaglandins 6kPGFI= (+) and PGE2 (A)
and NO2/NO3 (O) during the course of DSS-induced colitis. *p
< 0.05 vs. day O.
DSS concentration in the drinking water was
reduced to 2% (w/v) on the fifth day of the
treatment schedule, showed a significant
decrease of the inflammation score compared
with groups which had been treated with 10%
DSS for 2 or 4 days. Compared with the control
group, however, inflammatory activity was still
present (Fig. 2(c)).
Release of inflammatory mediators.. The mean
(_-t- S.E.M.) protein content was, respectively,
11.7 _+ 0.7, 4.0 __+ 1.0, 9.1 0.8, 9.7 _+ 0.4 and
10.9 _+ 0.4 mg/g wet tissue on days 0, 2, 4, 8
and 14. The mean (___ S.E.M.) MPO activity was,
respectively, 106 _+ 9.5, 94 22, 60+__ 13.7,
99+ 16.9 and 80 __+ 12.0 ng/g wet tissue, result-
ing in mean concentrations of 9.1, 23.5, 6.6, 10.2
and 7.3 ng MPO/mg protein.
The production of NO, 6kPGFla and PGE2 in
100 mg tissue decreased significantly during the
initial phase (d2-d4) of the inflammation (Fig.
3). The production of LTB4 and LTC4 was extre-
mely low in comparison with PGs (1-4 vs. 500-
3500 pg/mg wet tissue, data not shown) and did
not change significantly. The production of the
cytokines TNFa and IL-1[3 was only increased in
the first two days (initial phase) of DSS treat-
ment. The production of PAF was unchanged
during the initial phase, whereas a marked
increase of PAF production was observed (d8)
after the concentration of DSS was reduced (Fig.
4).
Discussion
Dextran sodium sulfate induced a diffuse
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FIG. 4. Production of cytokines TNF, ((+), units x 10-3) and IL-
1[ ((f), units x 10-1) and PAF (0) during the time-course of
DSS-induced colitis. *p < 0.05 vs. day O.
the mice when given according to the method
described by Okayasu et a/.5 A clear correlation
between macroscopic and microscopic inflamma-
tion scores was observed. Inflammation reached
maximal values of approximately 60% of full
scale after 4 days treatment with 10% DSS.
Further addition of 2% DSS to the drinking water
resulted in a degree of chronic inflammation,
resembling 25% of the total inflammation score.
The individual standard deviations of the groups
sacrificed at each time point during the course of
the disease are relatively small. Our observations
regarding a fast release of pro-inflammatory cyto-
kines confirmed the finding of Rachmilewitz et
a/.
18 that IL-1 was detected in high concentra-
tions during the onset of the inflammation in
TNB/ethanol-treated rats. Interleukin-1 was assoc-
iated with colonic myeloperoxidase activity,
representing neutrophil influx. In the TNB/
ethanol rat model, the highest LTB4 levels were
reached after 1 week, whereas TxB2 was unchan-
ged.
8 In DSS-induced colitis in mice, we now
observed a sequential release of cytokines (TNFa
and IL-1[3) and lipid mediators. The initial release
and subsequent effects of pro-inflammatory cyto-
kines have been reviewed recently by Radford-
Smith and Jewell.
19 It has been suggested
recently that TNFa might stimulate IL-8 produc-
2O tion, which in turn activates neutrophils. The
secondary release of PAF could result in an
increased vascular permeability, which might
induce mucus loss and diarrhoea. The formation
of the cyclooxygenase products 6kPGF= and
PGE2 was significantly decreased during the
initial phase of the inflammation. A similar profile
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was observed for nitric oxide (NO). Both NO
and prostacyclin synthase are highly susceptible
to attack by free radicals.
21 In our observations,
the elevated release of MPO on day 2 indeed
precedes the diminished elevation of NO. Endo-
thelial cells could be depleted and unable to
generate these bioactive substances. The forma-
tion of neutrophil aggregates has been described
in PAF-induced gastrointestinal damage,
22 where-
as it has been demonstrated that NO can prevent
23 neutrophil adhesion to the endothelium. A sig-
nifican increase of NO was observed after 8 days
of inflammation. This could be due to a second-
ary influx of activated macrophages which may
contribute to this phenomenon. Corticosteroids
are known to inhibit the production of both
eicosanoids
7 and the pro-inflammatory IL-I.
24
These non-selective inhibitory actions could
explain why both the initial and the chronic
phase of inflammation are successfully treated by
this group of compounds. Sulfasalazine derived
compounds such as 5-amino-salicylates (5-ASA)
non-selectively inhibit eicosanoid formation in
dextran sulfate induced colitis in mice,
25 whereas
we previously found that 5-ASA increases rather
than inhibits PAF synthesis.
16 This effect of 5-ASA
on PAF might explain the fact that exacerbations
during chronic colitis are well treated by 5-ASA
compounds, but total remission is not achieved
in many cases.
Further investigations with specific synthesis
inhibitors and soluble receptor antagonists are
needed to gain more insight in the importance of
the sequential release of pro- and anti-inflamma-
tory mediators during acute and chronic colitis.
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